UY27059A1 - Preparaciones para potenciar la inmunogenecidad de antígenos poco inmunogénicos - Google Patents

Preparaciones para potenciar la inmunogenecidad de antígenos poco inmunogénicos

Info

Publication number
UY27059A1
UY27059A1 UY27059A UY27059A UY27059A1 UY 27059 A1 UY27059 A1 UY 27059A1 UY 27059 A UY27059 A UY 27059A UY 27059 A UY27059 A UY 27059A UY 27059 A1 UY27059 A1 UY 27059A1
Authority
UY
Uruguay
Prior art keywords
immunogencity
preparations
power
immunogenic antigens
antigens
Prior art date
Application number
UY27059A
Other languages
English (en)
Inventor
Perez Rodriguez Rolando
Fernandez Molina Luis
Sanchez Ramirez Belinda
Suarez Pestana Eduardo
De La Barrera Aira
Mesa Pardillo Circe
De Leon Delgado Joel
Diaz Rodriguez Yildian
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU20000285A external-priority patent/CU23000A1/es
Priority claimed from CU20010167A external-priority patent/CU23009A1/es
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of UY27059A1 publication Critical patent/UY27059A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con los medios para hacer péptidos, polipéptidos, proteínas inmunológicas, sus correspondientes secuencias de ácidos nucleicos, células blanco de interés vacunal y sus lisados, sin hacer cambios estructurales en dichos antígenos, mediante su asociación con proteoliposomas de muy pequena talla. Adicionalmente se describe como estas composiciones pueden formularse solas o formando emulsiones con el adyuvante incompleto de Freund y también ser liofilizadas. En particular esta invención muestra como preparar composiciones inmunoestimuladoras capaces de generar respuestas inmunes antígeno-específicas incluso en huéspedes inmunocomprometidos, como son los que padecen de cáncer en infecciones de origen viral o bacterianas crónicas.
UY27059A 2000-12-06 2001-12-06 Preparaciones para potenciar la inmunogenecidad de antígenos poco inmunogénicos UY27059A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20000285A CU23000A1 (es) 2000-12-06 2000-12-06 Composiciones vacunales para la inmunoterapia activa específica del cáncer
CU20010167A CU23009A1 (es) 2001-07-12 2001-07-12 Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos

Publications (1)

Publication Number Publication Date
UY27059A1 true UY27059A1 (es) 2002-04-26

Family

ID=38812545

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27059A UY27059A1 (es) 2000-12-06 2001-12-06 Preparaciones para potenciar la inmunogenecidad de antígenos poco inmunogénicos

Country Status (20)

Country Link
US (1) US7776342B2 (es)
EP (1) EP1356822B1 (es)
JP (1) JP4210519B2 (es)
KR (1) KR100850473B1 (es)
CN (1) CN1291755C (es)
AR (1) AR031638A1 (es)
AT (1) ATE485833T1 (es)
AU (2) AU2002221519B2 (es)
BR (1) BRPI0116013B8 (es)
CA (1) CA2431188C (es)
DE (1) DE60143363D1 (es)
DK (1) DK1356822T3 (es)
EA (1) EA005138B1 (es)
HK (1) HK1063726A1 (es)
MX (1) MXPA03005032A (es)
NZ (1) NZ526282A (es)
PE (1) PE20020572A1 (es)
UY (1) UY27059A1 (es)
WO (1) WO2002045746A2 (es)
ZA (1) ZA200304411B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
EP1367395A1 (de) * 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
AR045815A1 (es) * 2003-10-09 2005-11-16 Ct Ingenieria Genetica Biotech Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano
WO2005111079A2 (en) * 2004-05-14 2005-11-24 The United States Of America As Represented By The Secretary Department Of Health And Human Services Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
WO2010003219A1 (en) * 2008-06-17 2010-01-14 Universite Laval Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines
TR201906323T4 (tr) * 2010-12-22 2019-05-21 Bayer Ip Gmbh Sığır türlerinde artırılmış bağışıklık yanıtı.
KR101323845B1 (ko) * 2011-01-21 2013-10-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
CA2904506A1 (en) * 2013-03-15 2014-09-18 Bioven 3 Limited Self-assembling synthetic proteins
CU24299B1 (es) * 2013-08-02 2017-12-08 Centro De Inmunología Molecular Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
HK1194912A2 (en) * 2013-09-17 2014-10-24 Bestop Group Holdings Ltd Growth factor concentrate and the use thereof
US10105306B2 (en) * 2013-09-17 2018-10-23 Bestop Group Holdings Limited Method of preparing a growth factor concentrate
CN106103467B (zh) * 2014-03-11 2019-12-31 艾克斯-马赛大学 与细胞膜神经节苷脂相互作用的嵌合肽
WO2018166542A1 (es) 2017-03-15 2018-09-20 Centro De Inmunologia Molecular Método para el tratamiento de pacientes con carcinomas
CA3076012A1 (en) * 2017-09-27 2019-04-04 L2 Diagnostics, Llc Erbb peptide pharmaceutical and vaccine compositions and therapeutics uses thereof for cancer
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
CN109865137A (zh) * 2019-01-23 2019-06-11 天德悦（北京）生物科技有限责任公司 经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
IT1206250B (it) * 1987-02-18 1989-04-14 Ist Farmacoterapico It Spa Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5679356A (en) 1992-07-08 1997-10-21 Schering Corporation Use of GM-CSF as a vaccine adjuvant
DE69428763T2 (de) * 1993-12-09 2002-08-01 Ct De Inmunologia Molecular Ci Monoklonale Antikörper gegen Ganglioside und deren Verwendung in der spezifischen, aktiven Immuntherapie gegen bösartige Tumoren
CU22420A1 (es) 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE69931749T2 (de) * 1998-01-16 2007-05-31 Biomira Usa Inc. Von membran-proteoliposomen patient-spezifischen bösartigen weissen blutzellen impstoff

Also Published As

Publication number Publication date
DE60143363D1 (de) 2010-12-09
EP1356822A2 (en) 2003-10-29
EA200300640A1 (ru) 2003-12-25
PE20020572A1 (es) 2002-07-31
ZA200304411B (en) 2004-07-29
MXPA03005032A (es) 2004-09-10
EP1356822B1 (en) 2010-10-27
DK1356822T3 (da) 2011-02-07
CA2431188C (en) 2010-09-07
AU2151902A (en) 2002-06-18
KR100850473B1 (ko) 2008-08-07
KR20030061838A (ko) 2003-07-22
US20020136735A1 (en) 2002-09-26
WO2002045746A3 (es) 2002-12-27
BR0116013A (pt) 2004-01-06
BRPI0116013B8 (pt) 2021-05-25
HK1063726A1 (en) 2005-01-14
NZ526282A (en) 2005-01-28
AU2002221519B2 (en) 2006-11-23
CA2431188A1 (en) 2002-06-13
WO2002045746A2 (es) 2002-06-13
US7776342B2 (en) 2010-08-17
JP2004523494A (ja) 2004-08-05
CN1291755C (zh) 2006-12-27
EA005138B1 (ru) 2004-12-30
AR031638A1 (es) 2003-09-24
CN1484532A (zh) 2004-03-24
JP4210519B2 (ja) 2009-01-21
ATE485833T1 (de) 2010-11-15
BRPI0116013B1 (pt) 2018-07-24

Similar Documents

Publication Publication Date Title
UY27059A1 (es) Preparaciones para potenciar la inmunogenecidad de antígenos poco inmunogénicos
AR014182A1 (es) Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
AR003125A1 (es) Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
CY1112105T1 (el) Ανοσογονα βακτηριακα κυστιδια με πρωτεϊνες εξωτερικης μεμβρανης
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
NO20023829D0 (no) Proteosom influensavaksine
EA200100425A1 (ru) Новые способы терапевтической вакцинации
BR0210216A (pt) Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante
EA201070329A1 (ru) Векторы и конструкции для доставки гриппозного антигена
CY1107570T1 (el) Ανοσογονικα πολυπεπτιδια κωδικοποιουμενα απο μινιγονιδια mage και οι χρησεις τους
BR0208874A (pt) Proteìnas superficiais de streptococcus pyogenes
BR0010323A (pt) Composições imunogênicas, kit e método de confecção da mesma para uso na imunização de um mamìfero
NO20081043L (no) Vaksine for fisk
DK2054431T3 (da) Konformere af bakterielle adhæsiner
WO2011056721A3 (en) Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
AR114627A1 (es) Composición inmunogénica
ATE389397T1 (de) Adjuvante zusammensetzungen
Nyari et al. Vaccination of koalas (Phascolarctos cinereus) against Chlamydia pecorum using synthetic peptides derived from the major outer membrane protein
BR0017136A (pt) Peptìdeos de ligação ao hla e seus usos.
AR051826A1 (es) Composiciones inmunogenicas de antigenos polipeptidicos de staphylococcus epidermidis
TW200833709A (en) Archaeal polar lipid aggregates for administration to animals
BR112021019826A2 (pt) Síntese otimizada de antígeno de plasmídeo de invasão b livre de célula e composições e métodos de uso relacionados
CO4650187A1 (es) COMPOSICION DE VACUNA PARA LA PREVENCION DE INFECCIONES PROVOCADAS POR CHLAMYDIA QUE COMPRENDEN LA PROTEINA PRINCIPAL DE LA MEMBRANA EXTERNA DE CHLAMYDIA COMBINADA CON UNA ENTEROTOXINA MUTADA TERMOLABIL DE E.coli